Content about Clopidogrel

December 13, 2013

A recent study commissioned by Intel revealed that patients are ready to embrace personalized care, all the way down to medications for their specific genetic makeup, and they want the freedom to get health care wherever and whenever it’s convenient for them.

Why is this important? Personalization — whether it is customized coupons and marketing or prescription medications — is here and will be critical in 2014. Consumers want more, and in the face of rising healthcare costs and a strained health care system, their healthcare is no exception.

A recent study commissioned by Intel revealed that patients are ready to embrace personalized care, all the way down to medications for their specific genetic makeup, and they want the freedom to get health care wherever and whenever it’s convenient for them.

November 13, 2013

A new study conducted by researchers at CVS Caremark and Brigham and Women's Hospital explored the impact of genetic testing on prescribing patterns for cardiovascular therapy.

WOONSOCKET, R.I. — A new study conducted by researchers at CVS Caremark and Brigham and Women's Hospital explored the impact of genetic testing on prescribing patterns for cardiovascular therapy and found that there is an opportunity to improve upon the information physicians and patients receive on the evolving body of evidence for pharmacogenomics.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 27, 2012

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

SILVER SPRING, Md. — Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

September 28, 2012

Supermarket chain Bi-Lo is adding the generic form of a blood-thinning drug to its generic-discount program.

JACKSONVILLE, Fla. — Supermarket chain Bi-Lo is adding the generic form of a blood-thinning drug to its generic-discount program.

The company announced Friday that patients could buy generic clopidogrel for $4 for a 30-day supply and $10 for a 90-day supply with the chain's Pharmacy Discount Card. The branded version of the drug, which recently became available as a generic, is marketed by Sanofi and Bristol-Myers Squibb.

August 30, 2012

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

DALLAS — Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

August 6, 2012

Winn-Dixie announced the generic form of Plavix (clopidogrel) now is available for $4 for 30-day and $10 for 90-day prescriptions as part of the company's prescription savings program.

JACKSONVILLE, Fla. — Winn-Dixie announced the generic form of Plavix (clopidogrel) now is available for $4 for 30-day and $10 for 90-day prescriptions as part of the company's prescription savings program.

Winn-Dixie recently launched a prescription savings program in all of its pharmacies that offers deep discounts on more than 400 generic medications and varied discounts on branded and other generic medication.

May 18, 2012

Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a generic version of a drug used to prevent clotting of the blood.

Dr. Reddy's announced Friday the launch of clopidogrel tablets in the 75-mg and 300-mg strengths. The drug is a generic version of Plavix, made by Bristol-Myers Squibb and Sanofi. As one of the first companies to submit a completed regulatory application for the 300 mg strength of the drug, Dr. Reddy's received 180 days of market exclusivity for it.

May 17, 2012

The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

May 16, 2012

Walmart and Sam's Club will be among the first retailers to offer a generic version of an antiplatelet drug.

BENTONVILLE, Ark. — Walmart and Sam's Club will be among the first retailers to offer a generic version of an antiplatelet drug.

Clopidogrel, the generic version of Plavix, will be available at both banners pharmacies on May 19. The patent for the Bristol-Myers Squibb/Sanofi drug officially expires Thursday.

April 11, 2012

Move over, Lipitor: There's a new top drug on the market, according to published reports.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

March 9, 2012

A regional retail pharmacy chain and a nearby school of pharmacy will collaborate on a study to evaluate the implementation of a pharmacogenetic program in a community pharmacy setting.

RALEIGH, N.C. — A regional retail pharmacy chain and a nearby school of pharmacy will collaborate on a study to evaluate the implementation of a pharmacogenetic program in a community pharmacy setting.

Kerr Drug announced Friday that it would work with the University of North Carolina Chapel Hill's Eshelman School of Pharmacy to explore the feasibility of a program for Sanofi's and Bristol-Myers Squibb's blood-thinning drug Plavix (clopidogrel bisulfate).

January 20, 2012

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot.

If the patent cliff were a sports team, Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin) would be its mascot. Because it’s the top-selling drug, well, ever — with 2010 sales well in excess of $7 billion in the United States alone — Lipitor’s loss of patent protection on Nov. 30, 2011, didn’t start or end the patent cliff but in many ways symbolized it.


September 28, 2011

Supermarket pharmacies could see a slight rise in gross profits next year as branded drugs lose patent protection and go generic, according to a new report by Moody's Investors Service.

NEW YORK — Supermarket pharmacies could see a slight rise in gross profits next year as branded drugs lose patent protection and go generic, according to a new report by Moody's Investors Service.

September 12, 2011

The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.


The issue of patent settlements, their effect on drug prices and availability, and by extension their legality has been around for a long time and will likely remain an issue for years to come. But according to a report released in May by the Federal Trade Commission, the settlements have been on the rise, increasing from 16 in 2009 to 31 in 2010.


August 16, 2011

A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

INDIANAPOLIS — A special group of patients who participated in a trial of a heart disease drug made by Daiichi Sankyo and Eli Lilly showed fewer heart attacks, strokes and deaths related to cardiovascular disease than patients taking a competing drug, according to an analysis of study results.

July 21, 2011

The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

WILMINGTON, Del. — The Food and Drug Administration has approved a drug made by AstraZeneca to reduce the rate of heart attacks in patients with acute coronary syndrome, the Anglo-Swedish drug maker said.

AstraZeneca announced the approval of Brilinta (ticagrelor), a blood-thinning drug, on Wednesday. The drug maker is touting the drug as an alternative to Plavix (clopidogrel), made by Sanofi and Bristol-Myers Squibb.

April 18, 2011

A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.

ST. PAUL, Minn. — A letter educating healthcare providers regarding a drug-drug interaction between prescription anticlotting drug Plavix (clopidogrel) and a proton-pump inhibitor has resulted in a reduction in the number of patients combining the two therapies, according to a new study by Prime Therapeutics released Monday.

April 5, 2011

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

NEW ORLEANS — Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

February 18, 2011

A whole slew of drugs will lose patent protection this year, opening up opportunities for generic drug makers to market their own versions. Most notable among these is Pfizer’s cholesterol-
lowering drug Lipitor (atorvastatin), the world’s top-selling drug, with U.S. sales of $7 billion during the 12 months ended September 2010, according to IMS Health.


February 10, 2011

This year’s upcoming $29 billion wave of margin-friendly generic pharmaceuticals will be as big a growth catalyst for supermarket pharmacies as it will be for their pureplay drug store cousins, Credit Suisse research analyst Ed Kelly stated in a note published Thursday.

NEW YORK — This year’s upcoming $29 billion wave of margin-friendly generic pharmaceuticals will be as big a growth catalyst for supermarket pharmacies as it will be for their pureplay drug store cousins, Credit Suisse research analyst Ed Kelly stated in a note published Thursday.

Conservative projection models place the generic impact at 3% to 5% accretive to 2012 earnings, he reported, given that the channel fills between 10% and 15% of all retail prescriptions.

October 6, 2010

The global pharmaceutical market will reach a value of $880 billion next year, according to...

NORWALK, Conn. The global pharmaceutical market will reach a value of $880 billion next year, according to a report by market research firm IMS Health.

 

IMS Health forecasted 5% to 7% growth in 2011 in its annual IMS Market Prognosis, compared with 4% to 5% growth this year.

 

 

March 29, 2010

The U.S. Patent and Trademark Office plans to uphold the patent protection of a blockbuster...

March 11, 2010

A popular drug for preventing blood clots may be less effective when taken by a...

March 3, 2010

Aims of becoming a leader in biotechnology headlined a meeting Thursday between Bristol-Myers Squibb and...